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The gut microbiome has been related to several features present in Glycogen Storage Dis-
eases (GSD) patients including obesity, inflammatory bowel disease (IBD) and liver disease.
Objectives
The primary objective of this study was to investigate associations between GSD and the
gut microbiota.
Methods
Twenty-four GSD patients on treatment with uncooked cornstarch (UCCS), and 16 healthy
controls had their faecal microbiota evaluated through 16S rRNA gene sequencing. Patients
and controls were�3 years of age and not on antibiotics. Faecal pH, calprotectin, mean
daily nutrient intake and current medications were recorded and correlated with gut
microbiome.
Results
Patients’ group presented higher intake of UCCS, higher prevalence of IBD (n = 04/24) and
obesity/overweight (n = 18/24) compared to controls (n = 0 and 06/16, respectively). Both
groups differed regarding diet (in patients, the calories’ source was mainly the UCSS, and the
intake of fat, calcium, sodium, and vitamins was lower than in controls), use of angiotensin-
converting enzyme inhibitors (patients = 11, controls = 0; p-value = 0.001) multivitamins
(patients = 22, controls = 01; p-value = 0.001), and mean faecal pH (patients = 6.23; controls =
7.41; p = 0.001). The GSD microbiome was characterized by low diversity and distinct
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microbial structure. The operational taxonomic unit (OTU) abundance was significantly influ-
enced by faecal pH (r = 0.77; p = 6.8e-09), total carbohydrate (r = -0.6; p = 4.8e-05) and sugar
(r = 0.057; p = 0.00013) intakes.
Conclusions
GSD patients presented intestinal dysbiosis, showing low faecal microbial diversity in com-
parison with healthy controls. Those findings might be due to the disease per se, and/or to
the different diets, use of UCSS and of medicines, and obesity rate found in patients.
Although the main driver of these differences is unknown, this study might help to under-
stand how the nutritional management affects GSD patients.
Introduction
Hepatic Glycogen Storage Diseases (GSD) are genetic disorders caused by deficient activity of
one of the enzymes involved in the glycogenolysis pathway. The global incidence is estimated
at 1 case per 20,000–43,000 live births. The most common types of GSD are GSD I, GSD III
and GSD Ixα [1].
In GSD I, glucose-6-phosphate cannot be dephosphorylated to free glucose. There are two
major subtypes of GSDI: Ia (~80%), caused by mutations in the G6PC gene, and GSD Ib
(~20%), caused by mutations in the SLC37A4 gene. The proteins produced from G6PC (cata-
lytic activity) and SLC37A4 (transporter) work together [2]. GSD Ia involves glycogenolysis
and gluconeogenesis, and the clinical manifestations are increased weight, hepatomegaly, fail-
ure to thrive, fasting hypoglycaemia, high lactate, hyperuricemia, nephromegaly and hyperlipi-
daemia [3]. In addition to the features presented in GSD Ia, GSD Ib also presents with
susceptibility to recurrent infections, impaired neutrophil and monocyte function, and inflam-
matory bowel disease (Crohn’s-like IBD) [1].
Mutations in the AGL gene cause GSD type III, in which the defective glycogen debranch-
ing enzyme blocks glycogenolysis, stopping the conversion of glycogen to glucose-1-phosphate
[4]. At the same time, gluconeogenesis is enhanced to help maintain endogenous glucose pro-
duction. Hepatomegaly in type III GSD generally improves with age, but affected individuals
may develop chronic liver disease (cirrhosis) and liver failure later in life [5].
GSD IX is caused by the inability of phosphorylase b kinase (PHKA) to break down the gly-
cogen in liver and/or muscle cells. Type IXα glycogenosis is an X-linked disease caused by
mutations in the alpha subunit of PHKA. The signs and symptoms typically begin in early
childhood, but GSD IX is usually milder than the other types [6].
The treatment for the aforementioned types of GSD involves nutritional adjustments pri-
marily, with the periodic and frequent administration of large amounts of uncooked corn-
starch (UCCS) and restriction of simple carbohydrates [7] to maintain normoglycaemia and
avoid glycogen storage. Usually, higher and frequent doses of UCCS are prescribed for type Ia
patients and lower doses for type IX patients. The dose is adjusted according to weight and
metabolic demand [8]. GSD III and IX patients may require a hyperproteic diet with fewer
restrictions for simple sugars. Sometimes additional medications may be necessary.
During the last decades, our understanding of the human being has changed. We know
now that the eukaryote cells encoded by our genome are not the only component of our body.
Symbiont prokaryotic cells inhabiting many cavities of our body provide metabolic functions
far beyond the scope of our own physiological capabilities [9]. These cells play an important
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role in health and disease states [10]. The gut microbes are the most studied human associated
microbial communities and consists of trillions of microbes and millions of functional genes
[11]. Healthy humans present a remarkable microbial diversity but with similar functions indi-
cating that different microbial communities are associated with a healthy microbiome [12].
The gut microbiome can be influenced by diet, lifestyle, drugs and genetics of the host [13],
and has been related to several features present in GSD patients including obesity, IBD and
liver disease [14]. This work aimed to investigate possible associations between GSD and the
gut microbiota.
Methods
This study was a cross-sectional, observational convenience sampling study, which included
24 GSD patients (Ia = 15, Ib = 5, III = 1, IXα = 3) and 16 healthy controls. All patients were
recruited from the outpatient clinics of the Medical Genetics Service at Hospital de Clı́nicas de
Porto Alegre (MGS-HCPA), Brazil from Jan/2016 to May/2017. As inclusion criteria, the sub-
jects (patients and controls) were� 3 years old and not on antibiotics. The GSD patients also
were required to: a) have a genetic diagnosis of GSD and b) be on treatment with UCCS. The
healthy controls were recruited by invitation as they came to routine appointments at Santa
Cecı́lia Basic Health Unit, Porto Alegre, Brazil. All subjects received a kit and printed instruc-
tions for stool collection, storage, and transport. They were also provided with printed instruc-
tions to record three days of dietary information. Each participant collected their own frozen
fecal sample and three-day dietary record and submitted them to an outpatient clinic during
their next routine check-up. Upon returning to the clinic, each participant answered a brief
questionnaire about personal features including weight and height, eating habits, intestinal
habits, medicines of recent and/or continuous usage and lifestyle. The study protocol was
approved by the Ethics Committee of Hospital de Clı́nicas de Porto Alegre (HCPA). All partic-
ipants and/or legal guardians signed an informed consent.
As a routine, GSD patients seen at the MGS-HCPA who are on UCCS therapy also receive
a multivitamin prescription. Despite optimum dietary treatment other drugs could also be pre-
scribed, mainly for type I patients, such as allopurinol, to prevent gout and urate nephropathy;
angiotensin converting enzyme inhibitors, to slow-down or prevent further deterioration of
renal function; citrate, to preventing or ameliorating urolithiasis and nephrocalcinosis, in
addition to correcting lactacidaemia; statins to treat hypercholesterolaemia [15]; and mainly
for Ib patients, G-CSF to treat neutropenia, neutrophil dysfunction and IBD; and the intestinal
anti-inflammatory mesalazine (5-amino-salicylic acid), also to treat IBD [16].
Nutritional assessment, clinical data and statistical analysis
Macro and micronutrients intake by the subjects were estimated from the three-day food rec-
ords through the Nutribase software (NB16Cloud, CyberSoft, Inc., Phoenix, AZ, USA). The
daily nutrient intake of each participant was the sum of the nutrients of each food item. The
average of the three-day intake was used for further analysis. Multivitamin consumption and
other medications were not included in the nutritional assessment but were considered as vari-
ables that potentially were modifying the gut microbial composition, so they were tested by
Permutational Multivariate Analysis of Variance. Clinical data, such as IBD and other relevant
conditions, were accessed from medical records. BMI-for-age and Z-scores were calculated
within the World Health Organization (WHO) AnthroPlus software suite. A qualitative classi-
fication for this data followed the WHO criteria [17].
Statistical analysis among the groups was performed using PASW Statistics for
Windows software (Vs18.0, 2009, SPSS Inc., Chicago, USA). Numerical variables were
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compared using the Mann-Whitney U test. Categorical variables were compared using X2,
Fisher’s exact test or Continuity Correction, when necessary (with statistical significant
determined by the threshold p� 0.05). Statistical analyses with the microbiome feature are
described below.
Bacterial DNA extraction, 16S rRNA gene amplifications and sequencing
The bacterial DNA was isolated from 0.3 mg of frozen faecal sample with QIAamp DNA
Stool Mini Kit (Qiagen, Valencia, CA, USA) (Qiagen) according to manufacturer instruc-
tions and stored at -20˚C until use. The NanoVue system (GE Healthcare, Chicago, IL,
USAGE Healthcare) was used to assess the quality of extractions for downstream applica-
tions. For the sequencing step, the library was prepared following the procedures
described by Barboza et al. [18]. Briefly, region V4 of 16S rRNA gene was amplified with
the barcoded bacterial/archaeal primers 515F and 806R [19] in a reaction containing 2U
of Platinum Taq DNA High Fidelity Polymerase (Invitrogen, Carlsbad, CA, USA), 4 μL
10X High Fidelity PCR Buffer, 2 mM MgSO4, 0.2 mM dNTPs, 0.1 μM of both the 806R
barcoded primer and the 515F primer, 25μg of Ultrapure BSA (Invitrogen, Carlsbad, CA,
USA) and approximately 50 ng of DNA template in a final volume of 25 μL. After an initial
denaturation step of 5 min at 95˚C, 30 cycles of 94˚C for 45 s, 56˚C for 45 s and 72˚C for 1
minute were performed, followed by a final extension step of 10 min at 72˚C. After visual-
ization on agarose gel 1.5%, the PCR products were purified with the Agencourt AMPure
XP Reagent (Beckman Coulter, Brea, CA, USA) and the final concentration of the PCR
product was quantified with the Qubit Fluorometer kit (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s recommendations. Finally, the reactions were combined in
equimolar concentrations to create a mixture composed of 16S gene amplified fragments
of each sample. This composite sample was used for library preparation with the Ion One-
Touch 2 System using the Ion PGM Template OT2 400 Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Sequencing was performed with Ion PGM Sequencing 400 on the
Ion PGM System using Ion 318 Chip v2.
16S profiling data analysis
The Fastq files exported from the Ion PGM System were analysed with the BMP Operating
System (BMPOS) [20] according to the recommendations of the Brazilian Microbiome
Project [21]. Briefly, an Operational Taxonomic Unit (OTU) table was built using reads
truncated at 200 bp and quality filtered with a maximum expected error of 0.5. After
removing singletons, the sequences were clustered into OTUs at cutoff of 97% similarity,
and chimeras were checked and removed to obtain representative sequences for each
microbial phylotype. Taxonomic classification was carried out in QIIME version 1.9.1
[22] based on the UCLUST method against the SILVA ribosomal RNA gene database ver-
sion v132 [23] with a confidence threshold of 80%. Downstream analyses were carried out
with dataset rarefied to the minimum library size [24,25] in the R environment [26] using
the phyloseq package [27] and vegan package [28]. The online software Microbiome Ana-
lyst [29] was used to further detect microbial biomarkers associated with GSD patients.
After Cumulative Sum Scaling (CSS) normalization [30], the dataset was analysed by the
non-parametric factorial Kruskal-Wallis (KW) sum-rank test followed by Linear Discrim-
inant Analysis [31]. To make sure the biomarkers observed were not only driven by IBD-
like patients, we performed one analysis using the full dataset and another analysis exclud-
ing all four IBD-like patients and matched controls.
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Faecal calprotectin assay and pH measurement
Frozen faecal samples of patients and controls were thawed and aliquoted at room temperature
(20˚C) to perform the pH measures and calprotectin assay. To determine the faecal pH, the
samples were diluted 1:10 (w/v) in distilled water. After homogenization and incubation for 5
min at room temperature, the faecal pH was measured by an electronic pH-meter (K39-1014B,
KASVI, PR, Brazil) three minutes after complete electrode immersion.
The faecal calprotectin was quantified from 100 mg of faecal sample with the RIDASC-
REEN Calprotectin test (R-Biopharm AG) according to the manufacturer’s instructions. Cal-
protectin is a calcium-/zinc-binding protein, highly stable and resistant to degradation by
intestinal contents (pancreatic secretions, proteases, and bacterial degradation). It is mainly
produced by neutrophils in inflammation and has been amply confirmed in intestinal inflam-
matory diseases [32]. Calprotectin was evaluated to verify gut inflammation across groups and
its influence over the number of OTUs. Due to the small sample size of GSD III and IXα, just
the subtypes Ia and Ib (groups containing >15% of total sample) were compared. Results for
GSD Ia and GSD Ib patients were presented as median (Q1-Q3) and as min-max to GSD III
and IXα. To test the correlation among calprotectin and OUT richness, patients who were on
mesalazine were excluded from analysis.
Results
The characteristics of the patients and controls are summarized in Table 1. The nutrient intake
varied significantly between groups (S1 Table); the largest variation observed was the higher
total carbohydrate and calorie intakes in the GSD group due to UCCS usage. The amount of
protein consumed (g) and the number of calories derived from proteins did not differ between
patients and controls. However, the percentage of total caloric intake from proteins was lower
in patients. Patients ingested less fat (g and Kcal/day) and had a lower percentage of fat in the
diet. Regarding micronutrients, patients’ diet was poor in calcium and sodium, and in vitamins
B3, H, D and E in comparison to the control group’s diet.
The intakes of macro and micronutrients were similar among all the GSD types, with some
kcal variation from carbohydrate intake due the difference in UCCS consumption among
groups (S2 Table).
Overall 16S rRNA sequencing results, sequence quality control and control
for confounding variables
After quality filtering of the 16S rRNA reads, a total of 1,786,582 high-quality sequences longer
than 200 bp were obtained. To analyse whether the number of sequences from each sample
was representative of the underlying bacterial community, sequence coverage was calculated
(S3 Table). An average of 44,664 sequences per sample was obtained with average sequence
coverage of 0.99 at the 3% dissimilarity level. This sequencing depth was sufficient to obtain
excellent representation of the microbial community in these samples.
Results for suspected confounding variables that potentially were modifying the gut micro-
bial composition are presented at Table 1 and S1 Table. The gut microbial communities were
not affected by sex, age, nor the nutritional status of the subjects tested. Faecal pH was lower in
patients (6.23) than in controls (7.41), and this variable affected the presence/absence and
abundance of the gut microbes, with a reduced OTU count in lower pH. Only 18% of controls
(n = 3) and 41% of patients (n = 10) used antibiotics within the 6 months prior to data collec-
tion. The use of antibiotics within the 6 months prior to sampling did not affect the presence/
absence of microbes (p = 0.252) nor microbial relative abundance (p = 0.179) in these samples.
Microbial dysbiosis in GSD
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Hepatic GSD is associated with an abnormal gut microbial community
The analysis of overall microbial community structure revealed significant differences between
patients and controls (Fig 1). According to the PERMANOVA, the microbial community
structure between patients and controls differed by the presence and absence of taxa (r2 =
0.182; p = 0.003) and by their relative abundances (r2 = 0.166; p = 0.001). The analysis indi-
cated that the relative abundance of taxa contributed 16% of the variation in the microbial
community between patients and controls while the presence/absence of specific taxa contrib-
uted 18% to that variation.
Microbial diversity as measured by richness of OTUs and by the Shannon diversity index
also differed significantly (p< 0.01) between patients and controls (Fig 2). On average, control
stool samples possessed 184 OTUs while the patients had only 100 OTUs. The average Shan-
non diversity index was 3.49 and 2.48 in controls and patients, respectively. Together, these
beta and alpha diversity analyses indicated that the GSD gut microbiome is characterized by
low diversity and distinct microbial structures.
Defining the main taxa associated with the gut microbiota of patients and
controls
Specific microbial phylotypes present within the gut community might drive the main differ-
ences observed in GSD patients. To find those microbes, biomarker screening analysis was





p-value1 Microbial community difference between patients and
controls
Euclidian Metric Bray-Curtis Metric
R2 p-value R2 p-value
Sex (M/F) 14/10 07/09 0.561 0.02942 0.287 0.02964 0.267
Age (yr) 12 (10–19.75) 12.5 (10–23.25) 0.579 0.02895 0.302 0.02775 0.340
Faecal pH 6.23 (5.42–7.16) 7.41 (7.10–7.98) 0.001 0.05938 0.005 0.08507 0.001
Inflammatory Bowel Disease (yes/no) 04/20 00/16 0.136 0.06746 0.009 0.05152 0.003
Abdominal pain complaint (yes/no) 09/15 01/15 0.032 0.05590 0.010 0.04845 0.009
Nutritional status�
(Obese or Overweight/Normal)
18/06 06/09† 0.044 0.05199 0.004 0.03423 0.121
UCCS intake (g/day) 309.50 (373.7–245.3) 00 0.001 0.03698 0.114 0.05594 0.001
Drugs (yes/no):
-Allopurinol 4/20 0/16 0.136 0.02477 0.436 0.02426 0.517
-Antibiotic usage
(last 6 months)
10/14 3/13 0.241 0.03047 0.252 0.03200 0.179
-ACE inhibitor 11/13 0/16 0.001 0.03351 0.203 0.03919 0.054
-Filgrastim (G-CSF) 5/19 0/16 0.071 0.06654 0.002 0.05377 0.008
-Mesalazine 3/21 0/16 0.262 0.03089 0.290 0.03389 0.109
-Multivitamin 22/2 1/15 0.001 0.04034 0.070 0.05545 0.003
-Potassium Citrate 3/21 0/16 0.262 0.02248 0.516 0.02407 0.551
-Proton Pump Inhibitors 2/22 0/16 0.508 0.03068 0.318 0.03087 0.173
-Statins 1/23 0/16 1.000 0.03312 0.286 0.02542 0.486
UCCS: uncooked cornstarch; ACE: Angiotensin-converting-enzyme inhibitor (enalapril maleate); G-CSF: G-colony stimulating factor. Significant (p<0.05) events are
highlighted in bold.
1 Numeric variables were reported as medians (Q1-Q3). Due to the not-normal distribution, numeric variables were subjected to the Mann-Whitney test. Qualitative
variables were reported as absolute frequency and tested by X2, Fisher’s test or Continuity Correction, as appropriate.
† Data for one control was missing. Weight and height were measured when subjects delivered the sample. In this case, a relative drove the sample to the hospital, thus
we were unable to do so.
https://doi.org/10.1371/journal.pone.0214582.t001
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performed at different taxonomic levels. A total of 14 phyla were detected within these sam-
ples. However, more than half of the community was dominated by only three phyla: Bateroi-
detes (58% in controls; 47% in patients), Firmicutes (34% in controls; 39% in patients) and
Proteobacteria (5.8% in controls; 10% in patients) (Fig 3). All of the other phyla had very low
relative abundances. LEfSe analysis identified three microbial phyla as biomarkers with Actino-
bacteria and Proteobacteria overrepresented in patients while Euryarchaeota was underrepre-
sented. In particular, Proteobacteria presented a very high LDA score (more than 3.9 orders of
magnitude), reflecting a marked increase in relative abundance in patients and consistently
low abundance in controls. Firmitutes had a marginally-significant difference between patients
and controls (p = 0.043 and LDA score = 4.53 but FDR = 0.07).
At the genus level, nineteen microbial biomarkers were different, both in terms of statistics
and biological consistency, between patients and controls (Table 2). Those genera were higher
in controls. In patients, those genera were in low abundance and in some cases totally absent.
The lack of those microbes might be reflected in the alpha and beta diversity results as men-
tioned previously (Figs 1 and 2). Besides, Lactobacillus and Escherichia/Shigella were found to
be dominant in patients with a very high LDA score (4.36 and 3.89, respectively), highlighting
the biological importance of those microbes in GSD. To remove any biases caused by patients
with IBD-like symptoms (n = 4), all IBD-like patients and their respective controls were
removed from the dataset and a new biomarker analysis was performed (Table 2). Similar
trends as observed within the full dataset were still present in this reduced dataset. However,
the Lactobacillus genus, found previously in higher abundance in patients was not observed
within the dataset without IBD-like patients. On the other hand, Escherichia/Shigella was still
found to be more abundant in patients than in controls (LDA score = 3.85).
Fig 1. Principal coordinates analysis (PCoA) based on Bray Curtis distance matrix (A) and Euclidean distance matrix (B) show
the separation of gut microbiomes between GSD patients and controls. Each point represents a microbial community from one
subject; colours indicate the treatment.
https://doi.org/10.1371/journal.pone.0214582.g001
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Correlations between the gut microbiota, diet, faecal pH and gut inflammation
Spearman correlations were calculated between the microbiome, diet, faecal pH and calprotec-
tin (Fig 4).
The faecal pH values varied between patients and controls (Table 1), and this was important
for shaping their respective differences in gut microbiomes. Differences were determined with
the Euclidian distance matrix (for presence/absence of taxa) and the Bray Curtis distance
matrix (for relative microbial abundance). Faecal pH was correlated with the total number of
microbial OTUs such that higher faecal pH seemed to support more OTUs.
Microbial richness correlated negatively with total carbohydrate but positively with simple
carbohydrates (sugar). Calprotectin seemed to have no influence over the microbiome in
terms of the number of OTUs (Fig 4). In addition, there was no correlation between this
inflammatory marker and gut microbial richness.
Fig 2. Alpha diversity measurements of microbial communities in the GSD patients and control groups. Each panel represents one alpha diversity
measure: Richness = total number of OTUs observed, Shannon = microbial index of diversity. Boxes span the first to third quartiles; the horizontal line within
the boxes represents the median. Whiskers extending vertically from the boxes indicate variability outside the upper and lower quartiles. ��� indicates a
statistical difference between treatments at cutoff p� 0.001.
https://doi.org/10.1371/journal.pone.0214582.g002
Microbial dysbiosis in GSD
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Discussion
This is the first study about the fecal microbiota of GSD patients. In hepatic GSD, high and
periodic amounts of UCCS plus dietetic restriction of fast-digestion carbohydrates are the
Fig 3. The average relative abundance of phyla found in GSD patients and healthy controls. Phyla followed by an asterisk (�) are different, both in terms of
statistics and biological consistency, between patients and controls at p and FDR� 0.05: Euryarchaeota (LDA score = 1.75), Actinobacteria (LDA score = 3.06)
and Proteobacteria (LDA score = 3.94). Firmicutes was marginally significantly different with p = 0.064, LDA score = 4.52 and FDR = 0.112.
https://doi.org/10.1371/journal.pone.0214582.g003
Microbial dysbiosis in GSD
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Table 2. Microbial biomarkers differentiating patients with hepatic glycogenosis diseases and healthy controls.
Microbial genus Patients Controls p-values FDR LDA score
Relative abundance (%) (log 10)
Full dataset n = 24 n = 16
Lactobacillus 11.31 0.04 0.009 0.025 4.36
Escherichia/Shigella 6.70 0.96 0.003 0.013 3.89
Alistipes 2.77 9.12 0.005 0.018 -3.22
Subdoligranulum 1.59 1.00 0.012 0.029 2.42
Lachnospiraceae NK4A136 group 1.44 0.89 0.003 0.013 2.48
Faecalibacterium 1.00 3.52 0.016 0.036 -2.98
Ruminococcaceae UCG 002 0.98 3.09 0.001 0.007 -2.79
Bifidobacterium 0.78 0.19 0.004 0.018 3.1
Ruminococcus gnavus group 0.70 0.14 0.007 0.022 3.03
Phascolarctobacterium 0.53 1.31 0.015 0.035 -2.56
Blautia 0.26 0.53 0.002 0.012 -1.55
Odoribacter 0.25 0.53 0.011 0.028 -1.87
Barnesiella 0.22 0.98 0.009 0.025 -2.46
Roseburia 0.18 1.19 0.002 0.011 -2.78
Christensenellaceae R 7 group 0.14 0.80 0.000 0.002 -2.22
Ruminococcaceae UCG 003 0.10 0.60 0.000 0.003 -2.27
Lachnospiraceae UCG 008 0.04 0.26 0.004 0.018 -1.78
Ruminococcaceae UCG 005 0.03 0.25 0.000 0.002 -1.9
Eubacterium hallii group 0.02 0.08 0.000 0.002 -1.39
Anaerostipes 0.01 0.11 0.001 0.009 -1.55
Coprococcus 1 0.01 0.03 0.000 0.005 -0.95
Family XIII AD3011 group 0.01 0.05 0.000 0.002 -1.21
Family XIII UCG 001 0.00 0.03 0.001 0.007 -1.13
Methanobrevibacter 0.00 0.17 0.001 0.007 -1.78
Ruminococcaceae NK4A214 group 0.00 0.08 0.001 0.007 -1.5
Dataset without IBD-like patients� n = 20 n = 14
Escherichia/Shigella 6.47 0.92 0.003 0.027 3.85
Alistipes 2.97 9.76 0.008 0.039 -3.28
Ruminococcaceae UCG 002 1.12 3.07 0.004 0.028 -1.38
Bifidobacterium 0.81 0.08 0.003 0.027 3.2
Phascolarctobacterium 0.22 1.38 0.004 0.028 -2.74
Christensenellaceae R 7 group 0.17 0.76 0.001 0.016 -2.16
Blautia 0.14 0.39 0.001 0.017 -2.08
Ruminococcaceae UCG 003 0.11 0.61 0.001 0.016 -2.3
Roseburia 0.10 1.15 0.004 0.028 -2.83
Lachnospiraceae UCG 008 0.04 0.19 0.011 0.047 -1.57
Ruminococcaceae UCG 005 0.03 0.20 0.001 0.016 -1.76
Eubacterium hallii group 0.02 0.07 0.000 0.016 -1.32
Anaerostipes 0.01 0.07 0.010 0.047 -1.28
Coprococcus 1 0.01 0.02 0.008 0.039 -0.77
Family XIII AD3011 group 0.01 0.04 0.001 0.017 -1.14
Family XIII UCG 001 0.00 0.03 0.001 0.016 -1.15
Methanobrevibacter 0.00 0.17 0.003 0.027 -1.81
(Continued)
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Table 2. (Continued)
Microbial genus Patients Controls p-values FDR LDA score
Relative abundance (%) (log 10)
Ruminococcaceae NK4A214 group 0.00 0.08 0.003 0.027 -1.53
� Four IBD-like (Inflammatory Bowel Disease) patients and matched controls were excluded from the dataset to make sure the biomarkers observed were not only
driven by these patients.
https://doi.org/10.1371/journal.pone.0214582.t002
Fig 4. Correlations between the microbiota and diet, faecal pH, and gut inflammation.
https://doi.org/10.1371/journal.pone.0214582.g004
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main way to treat the genetic impairment in the glycogenolytic pathway. Our data suggest that
the overload of UCCS can lead to low fecal pH by favouring some bacterial genera capable of
utilizing complex carbohydrates in detriment of others. The low fecal pH, in turn, also acts as
an environmental selection factor to the bacteria in the lumen. Dysbiosis has been associated
with IBD and obesity. IBD includes inflammatory bowel diseases of unknown aetiology and
has two main forms: ulcerative colitis and Crohn’s disease (CD). CD is a chronic disease that
can affect any region in the digestive tract but is more likely to involve the small and large
intestines and the perianal region [33]. Enteropathy is related to type I patients, and despite
GSD Ib patients are classically described as prone to IBD-Crohn’s-like due the impaired neu-
trophil activity, this does not explain why patients with GSD Ia also displayed serologic mark-
ers altered for IBD, even if asymptomatic [34]. Its not clear if UCCS is the cause of obesity in
GSD patients [35], but the microbiome might be associated with it. Here we discuss why the
changes in microbiota could be considered as a factor of influence in the phenotype of these
patients and why the UCCS usage, even though not exclusively, is an important factor that
contribute to that.
Since the introduction of UCCS treatment for GSD, the focus changed from mortality to
morbidity and control of long-term complications [36], such as metabolic syndrome and
related symptoms [37,38]. GSD type I patients are prone to obesity, and it is suspected that
UCCS contributes to the aforementioned features [35,39]. GSD I patients also are subject of
heavier doses of UCCS and more restrict diet in comparison with types III and IX [35].
Regarding antibiotics, although its usage clearly drives changes in the gut microbial commu-
nity, subjects who were treated with antibiotics within 6 months prior to data collection, but
not during the study itself, were not affected by the previous antibiotic usage.
We found that the phyla Actinobacteria and Proteobacteria were overrepresented in patients
while the Euryarchaeota was underrepresented. The microbiome of GSD patients present low
diversity and was highly dominated by Escherichia/Shigella.
One possible driver of the differences in gut microbiomes between patients and controls is
UCCS overload, which creates an acidic environment [34,40]. In the human body, acids are
generated by regular metabolic activities and through the daily intake of food [41]. Fecal pH
was lower in patients than controls and stool acidification might lead to an alteration in the rel-
ative abundances of fermenting bacteria, decreasing the conversion of unabsorbable starches
to short chain fatty acids (SCFAs) [34].
SCFAs, including butyrate, are compounds made by bacteria in the gut that affect several
physiologic functions and serve anti-inflammatory roles [42]. Fecal pH was associated with
beta diversity and bacterial families belonging to the Clostridia class, an important producer of
butyrate in the gut. Several genera of SCFA-producing bacteria—Coprococcus, Blautia, Anae-
rostipes, Odoribacter and Faecalibacterium—were decreased in patients. Those genera were
also identified in paediatric patients with Crohn’s Disease [43]. Besides, Coprococcus and Fae-
calibacterium were found to have significantly low abundance in patients with nonalcoholic
fatty liver disease, independently of body mass index and insulin resistance [43].
The bacterial species residing within the mucous layer of the colon may influence whether
host cellular homeostasis is maintained or inflammatory mechanisms are triggered. A mutual-
istic relationship between the colonic microbiota, their metabolic products and the host
immune system is likely involved [44]. The phylum Proteobacteria was more abundant in
patients than in controls while the phylum Euryarchaeota was less abundant. Proteobacteria is
a gram-negative phylum with an outer membrane mainly composed of lipopolysaccharides
(LPS), which are known to sustain systemic levels of low-grade inflammation [45]. Higher lev-
els of Proteobacteria can be considered a strong marker of dysbiosis [46]. This phylum is prev-
alent in patients with liver cirrhosis [47]. Several serological markers for IBD were altered in
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GSD-Ia patients [34], and GSD Ib patients are prone to IBD CD-like. Despite the fact that cal-
protectin seemed not to influence the number of OTUs gut inflammation (calprotectin
>50μg/g) was verified in several patients. GSD type Ib patients have shown a concentration of
calprotectin�50μg/g, except for one patient, who had an active IBD diagnosed in the same
week. This might be due to a remission state and the use of anti-inflammatory mesalazine by
these patients.
In general, dysbiosis can be categorized as a) loss of beneficial organisms, b) excessive
growth of potentially harmful organisms and c) loss of overall microbial diversity. These three
categories often occur at the same time [48]. Dysbiosis has been implicated in a wide range of
diseases, including IBD, liver disease and obesity, that are secondary manifestations in GSD
patients [49]. The reason for dysbiosis remains unclear, but the overload of UCCS contributes
to those characteristics. The food intake records showed a difference in the intake of calories,
mainly due to the administration of UCCS in patients, as well as a difference in microbial sig-
nature that is known to be related to obesity. It is not known whether these microbiome
changes are a cause or a consequence of the pathophysiologies. However, correcting the dys-
biosis can improve health in some patients [50–52]. Dysbiosis can also provide biomarkers for
disease detection and management [53].
Conclusion
In this study, we reported significant alterations in the intestinal environments of GSD patients
versus healthy controls. Microbiota can be affected by abiotic and biotic factors, namely pH
and inflammation, and the differences in these factors between patients and controls might be
linked to both genetic disease and UCCS consumption. Several bacterial taxa were different in
GSD patients than in controls, and those groups are consistent with the secondary phenotypic
manifestations of GSD. The microbiome patterns of these patients may reinforce immune-
metabolic pathways that already are altered by genetic impairment, and may also be a factor in
the differential individual response to treatment. Patients may gain health and quality of life
from the restoration of gut microbial diversity that has been diminished by high UCCS intake.
Future research therefore should investigate ways to manipulate the gut microbiome and clar-
ify the possible effects of doing so.
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